Palisade Bio Management
Management criteria checks 1/4
Palisade Bio's CEO is J. Finley, appointed in Apr 2021, has a tenure of 3.67 years. total yearly compensation is $1.28M, comprised of 40.7% salary and 59.3% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth $23.04K. The average tenure of the management team and the board of directors is 2.5 years and 0.8 years respectively.
Key information
J. Finley
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 40.7% |
| CEO tenure | 3.7yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.5yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Palisade Bio: Guarding Intestinal Integrity
Nov 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$14m |
| Dec 31 2023 | US$1m | US$520k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$614k | US$441k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$358k |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$1m | US$365k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$532k | US$293k | -US$10m |
Compensation vs Market: J.'s total compensation ($USD1.28M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.
CEO
J. Finley (67 yo)
3.7yrs
Tenure
US$1,277,100
Compensation
Mr. J. D. Finley serves as its Chief Executive Officer of Palisade Bio, Inc. since 2023 and has been its Director since February 2023. He serves as the Chief Financial Officer at Palisade Bio, Inc. (Altern...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 3.7yrs | US$1.28m | 1.01% $ 23.0k | |
| COO & Chief Medical Officer | 1.3yrs | US$738.81k | 0.29% $ 6.6k | |
| Head of Translational Science & Medicine | less than a year | no data | no data | |
| Senior VP of Finance & Corporate Controller | 6.5yrs | no data | no data |
2.5yrs
Average Tenure
Experienced Management: PALI's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 1.8yrs | US$1.28m | 1.01% $ 23.0k | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Chairman of the Board | 3.7yrs | US$87.23k | 0.28% $ 6.4k | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
0.8yrs
Average Tenure
67yo
Average Age
Experienced Board: PALI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 13:03 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Palisade Bio, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Aydin Huseynov | Ladenburg Thalmann & Company |
| Jason McCarthy | Maxim Group |